Pharma Pass LLC

Laboratoires Fournier Sa

Schwarz Pharma Ag

Laboratories Fournier S.a.

Valeant International (barbados) Srl

Laboratoires Fournier

Other

Drugtech Corporation

Ucb, Inc.

Labaratoires Fournier, S.a.

Biovail Laboratories International S.r.l.

Biovail Laboratories, Inc.

Acino Pharma Ag

Laboratoires Fournier Sas

Pawan Seth

Andre Stamm

Andr&eacute; Stamm

Paul Maes

André Stamm

Benoît Schmitt

Benoit Schmidtt

Paul J Maes

The invention provides new benzimidazole compositions, comprising: (a) a core containing said benzimidazole active ingredient; (b) an intermediate layer; and (c) an enteric layer; said core being substantially free of binder. The invention also provides a process for manufacturing the composition of the invention.

Composition comprising a benzimidazole and process for its manufacture

The invention provides processes using suspensions to produce fenofibrate compositions. The resulting fenofibrate compositions can be made in the form of a capsule.

Process for producing fenofibrate tablets

The invention provides processes using suspensions to produce fenofibrate compositions. The resulting fenofibrate compositions can be made in the form of a tablet.

The present invention relates to a modified release composition of at least one form of tramadol which is a delayed and extended release composition for oral administration suitable for once daily dosing. That composition comprises a core comprising at least one form of tramadol selected from the group consisting of tramadol, racemic mixtures thereof, enantiomers thereof, pharmaceutically acceptable salts thereof, and combinations thereof in combination with a pharmaceutically acceptable excipient. That composition further comprises a modified release coating which substantially surrounds said core. The compositions of the invention provide delayed and extended release of said at least one form of tramadol such that the mean plasma concentration of the at least one form of tramadol reaches a therapeutically effective level at a time which is after at least about 3 hours after first administration.

Modified release formulations of at least one form of tramadol

Modified release compositions of at least one form of tramadol

The invention provides fenofibrate tablets comprising granulates, wherein the granulates can comprise carrier particles, micronized fenofibrate, and at least one hydrophilic polymer.

Fenofibrate pharmaceutical composition having high bioavailabilty

The invention provides an immediate-release fenofibrate composition comprising (a) an inert hydrosoluble carrier covered with at least one layer containing fenofibrate in a micronized form having a size less than 20 &#x3bc;m, a hydrophilic polymer and, optionally, a surfactant, the polymer making up at least 20% by weight of (a); and (b) optionally one or several outer phase(s) or layer(s). The invention also provides a method for preparing said composition.

Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it

The invention provides compositions comprising micronized fenofibrate, where the compositions have a dissolution of at least 10% in 5 minutes, 20% in 10 minutes, 50% in 20 minutes and 75% in 30 minutes, as measured using the rotating blade method at 75 rpm according to the European Pharmacopoeia, in a dissolution medium constituted by water with 2% by weight polysorbate 80 or 0.025 M sodium lauryl sulfate.

Fenofibrate pharmaceutical composition having high bioavailability

The invention provides suspensions of micronized fenofibrate. The suspensions can comprise micronized fenofibrate in a solution of hydrophilic polymers. The suspensions can further comprise one or more surfactants.

The invention provides fenofibrate compositions comprising granulates. The granulates can comprise micronized fenofibrate, inert hydrosoluble carrier particles, hydrophilic polymers, and, optionally, surfactants.

The invention relates to a pharmaceutical composition comprising a therapeutically effective amount of levodopa and of carbidopa, dispersed in a hydrophilic matrix, said composition further comprising an organic acid. A subject of the invention is also a process for preparing the composition, comprising granulation, in particular in a fluidized bed, of the various components and compression of the granules obtained.

Composition with sustained release of levodopa and carbidopa

The invention provides a sustained release composition free of food effect comprising a core comprising an active agent except for carbamazepine or verapamil, and a coating comprising, based on the weight of the coating, from 30 to 80% of a gastroresistant polymer and from 10 to 40% of a hydrophilic silicon dioxide. The invention also provides a method of alleviating food effect in a pharmaceutical composition. The invention also provides a dispersion useful thereof.

Sustained release pharmaceutical composition free of food effect

The invention provides a delayed release tablet, comprising: (i) a core comprising an active ingredient selected from the group consisting of oxybutynin hydrochloride, propranolol hydrochloride, buspiron hydrochloride, niacin, cetirizin hydrochloride, cerivastin sodium, metoprolol fumarate, and alendronate sodium., and conventional excipients; and (ii) a coating consisting essentially of a water-insoluble, water-permeable film- forming polymer, a plasticizer and a water-soluble polymer.

Tablet comprising a delayed release coating

The invention provides a solid composition comprising glipizide which is not in an amorphous form; polyethylene oxide; the balance consisting of conventional additives; and a functional coating; exhibiting a dissolution profile such that after 4 hours, from 10 to 30% of the glipizide is released, after 8 hours, from 40 to 60% of the glipizide is released, after 12 hours, from 80 to 100% of the glipizide is released.

Growing community of inventors

Irvine, CA, United States of America

Pawan Seth